INmune Bio Statistics

Total Valuation

INmune Bio has a market cap or net worth of $159.84 million. The enterprise value is $141.78 million.

Market Cap	159.84M
Enterprise Value	141.78M

Important Dates

The next estimated earnings date is Monday, August 5, 2024, after market close.

Earnings Date	Aug 5, 2024
Ex-Dividend Date	n/a

Share Statistics

INmune Bio has 19.78 million shares outstanding. The number of shares has increased by 0.45% in one year.

Shares Outstanding	19.78M
Shares Change (YoY)	+0.45%
Shares Change (QoQ)	+0.02%
Owned by Insiders (%)	32.20%
Owned by Institutions (%)	15.38%
Float	13.41M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1,220.17
Forward PS	15,686.45
PB Ratio	5.66
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1,082.29
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.71, with a Debt / Equity ratio of 0.28.

Current Ratio	1.71
Quick Ratio	n/a
Debt / Equity	0.28
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -86.20% and return on invested capital (ROIC) is -95.68%.

Return on Equity (ROE)	-86.20%
Return on Assets (ROA)	-58.40%
Return on Capital (ROIC)	-95.68%
Revenue Per Employee	$7,706
Profits Per Employee	-$2.03M
Employee Count	17
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.22% in the last 52 weeks. The beta is 1.94, so INmune Bio's price volatility has been higher than the market average.

Beta (5Y)	1.94
52-Week Price Change	-10.22%
50-Day Moving Average	9.12
200-Day Moving Average	10.00
Relative Strength Index (RSI)	43.85
Average Volume (20 Days)	237,857

Short Selling Information

The latest short interest is 2.14 million, so 10.81% of the outstanding shares have been sold short.

Short Interest	2.14M
Short Previous Month	1.99M
Short % of Shares Out	10.81%
Short % of Float	15.96%
Short Ratio (days to cover)	10.53

Income Statement

In the last 12 months, INmune Bio had revenue of $131,000 and -$34.50 million in losses. Loss per share was -$1.92.

Revenue	131,000
Gross Profit	131,000
Operating Income	-34.60M
Pretax Income	-34.50M
Net Income	-34.50M
EBITDA	-34.50M
EBIT	-34.50M
Loss Per Share	-$1.92

Full Income Statement

Balance Sheet

The company has $26.00 million in cash and $7.94 million in debt, giving a net cash position of $18.06 million or $0.91 per share.

Cash & Cash Equivalents	26.00M
Total Debt	7.94M
Net Cash	18.06M
Net Cash Per Share	$0.91
Equity (Book Value)	28.22M
Book Value Per Share	1.43
Working Capital	12.37M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-18.32M
Capital Expenditures	n/a
Free Cash Flow	-18.32M
FCF Per Share	-$1.02

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -26,413.74% and -26,333.59%.

Gross Margin	100.00%
Operating Margin	-26,413.74%
Pretax Margin	-26,333.59%
Profit Margin	-26,333.59%
EBITDA Margin	-26,333.59%
EBIT Margin	-26,333.59%
FCF Margin	-13,980.92%

Dividends & Yields

INmune Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.45%
Shareholder Yield	-0.45%
Earnings Yield	-21.58%
FCF Yield	-11.46%

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (5Y)	302.39%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

INmune Bio has an Altman Z-Score of -0.67 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.67
Piotroski F-Score	2